CO2019006059A2 - Anticuerpos monoclonales anti-alfa-sinucleína para prevenir la agregación de tau - Google Patents

Anticuerpos monoclonales anti-alfa-sinucleína para prevenir la agregación de tau

Info

Publication number
CO2019006059A2
CO2019006059A2 CONC2019/0006059A CO2019006059A CO2019006059A2 CO 2019006059 A2 CO2019006059 A2 CO 2019006059A2 CO 2019006059 A CO2019006059 A CO 2019006059A CO 2019006059 A2 CO2019006059 A2 CO 2019006059A2
Authority
CO
Colombia
Prior art keywords
alpha
monoclonal antibodies
tau aggregation
synuclein monoclonal
prevent tau
Prior art date
Application number
CONC2019/0006059A
Other languages
English (en)
Inventor
Karina Fog
Jeppe Falsig Pedersen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CO2019006059A2 publication Critical patent/CO2019006059A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

RESUMEN La invención se refiere a un nuevo uso de anticuerpos monoclonales anti-alfa-sinucleína. Los anticuerpos pueden usarse para prevenir la agregación de tau y, por lo tanto, para tratar taupatías tales como la enfermedad de Alzheimer.
CONC2019/0006059A 2016-12-22 2019-06-11 Anticuerpos monoclonales anti-alfa-sinucleína para prevenir la agregación de tau CO2019006059A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201600782 2016-12-22
DKPA201700016 2017-01-05
PCT/EP2017/083994 WO2018115225A1 (en) 2016-12-22 2017-12-21 Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation

Publications (1)

Publication Number Publication Date
CO2019006059A2 true CO2019006059A2 (es) 2019-06-19

Family

ID=61022287

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0006059A CO2019006059A2 (es) 2016-12-22 2019-06-11 Anticuerpos monoclonales anti-alfa-sinucleína para prevenir la agregación de tau

Country Status (14)

Country Link
US (1) US10364286B2 (es)
EP (1) EP3558364A1 (es)
JP (1) JP7300990B2 (es)
KR (1) KR102584663B1 (es)
CN (1) CN110114088B (es)
AU (1) AU2017384681A1 (es)
BR (1) BR112018017172A2 (es)
CA (1) CA3046857A1 (es)
CL (1) CL2019001735A1 (es)
CO (1) CO2019006059A2 (es)
IL (1) IL267559A (es)
MX (1) MX2019007480A (es)
RU (1) RU2760334C2 (es)
WO (1) WO2018115225A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
LT3484916T (lt) 2016-07-12 2021-04-26 H. Lundbeck A/S Antikūnai, būdingi hiperfosforilintam tau, ir jų naudojimo būdai
MX2019005594A (es) 2016-11-15 2019-07-04 H Lundbeck As Agentes, usos y metodos para el tratamiento de la sinucleinopatia.
WO2018109058A1 (en) 2016-12-16 2018-06-21 H. Lundbeck A/S Agents, uses and methods
JP7217710B2 (ja) 2017-01-04 2023-02-03 ハー・ルンドベック・アクチエゼルスカベット 眼疾患の治療のための過リン酸化タウに特異的な抗体
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
JP2022502369A (ja) * 2018-10-07 2022-01-11 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア α−シヌクレインの立体配座特異的エピトープ、それに対する抗体、およびそれに関連する方法
CN112888708A (zh) * 2018-10-19 2021-06-01 扬森疫苗与预防公司 抗突触核蛋白抗体
KR102239512B1 (ko) * 2020-09-10 2021-04-12 서울대학교산학협력단 다중기능성 마이크로캡슐 조성물 및 그 제조방법
WO2022079297A1 (en) * 2020-10-16 2022-04-21 Ac Immune Sa Antibodies binding to alpha-synuclein for therapy and diagnosis
US20240009285A1 (en) * 2020-11-11 2024-01-11 Regenerative Research Foundation Compositions and Methods for Controlled Protein Degradation in Neurodegenerative Disease
CA3210385A1 (en) * 2021-03-24 2022-09-29 Jijun Dong Upar antibodies and fusion proteins with the same
CN113912716B (zh) * 2021-12-15 2022-03-01 北京凯祥弘康生物科技有限公司 针对α-突触核蛋白抗原的抗体及其应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
DK0804070T3 (da) 1993-03-09 2000-08-07 Genzyme Corp Fremgangsmåde til isolering af proteiner fra mælk
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
WO2000002053A2 (en) * 1998-07-03 2000-01-13 Innogenetics N.V. Differential diagnosis of neurodegeneration
MXPA02000962A (es) 1999-07-29 2002-07-02 Medarex Inc Anticuerpos monoclonales humanos para her2/neu.
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
WO2002004482A1 (en) 2000-07-07 2002-01-17 Panacea Pharmaceuticals, Inc. Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
ATE378403T1 (de) 2000-11-30 2007-11-15 Medarex Inc Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
AU2002345843A1 (en) 2001-06-22 2003-01-08 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005013889A2 (en) 2003-05-19 2005-02-17 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in lewy body disease
US7674599B2 (en) * 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
JP2006031250A (ja) 2004-07-14 2006-02-02 Fuji Xerox Co Ltd 通信装置およびその制御方法
US20060205024A1 (en) * 2005-03-08 2006-09-14 Sun Health Research Institute Method to diagnose and evaluate progression of Alzheimer's disease
CA2657953A1 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
BRPI0619056A2 (pt) 2005-11-28 2011-09-20 Genmab As anticorpo monovalente, método para preparar e produzir um antcorpo monovalente, construção de ácido nucleico, célula hospedeira, imunoconjugado, uso de um anticorpo monovalente, e, composição farmacêutica
HUE028731T2 (en) 2007-02-23 2016-12-28 Prothena Biosciences Ltd Prevention and treatment of synucleinopathic and amyloidogenic diseases
DK3067066T3 (da) * 2007-02-23 2019-05-20 Prothena Biosciences Ltd Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
EP3255144A1 (en) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin
JP2010536907A (ja) * 2007-08-31 2010-12-02 ニューリミューン セラピューティクス エイジー 患者にアミロイドーシスおよびタンパク質凝集性障害における特異的免疫応答をもたらす方法
TR201901497T4 (tr) 2008-04-29 2019-02-21 Bioarctic Ab Alfa-sinüklein ile ilişkili bozukluklar için terapötik ve teşhis yöntemlerinde kullanıma yönelik antikorlar ve aşılar.
EP2470211B1 (en) * 2009-08-28 2016-01-27 The Board of Regents of The University of Texas System Antibodies that bind tau oligomers
EP2539366B1 (en) * 2010-02-26 2017-11-08 BioArtic Neuroscience AB Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
US8697076B2 (en) * 2011-04-27 2014-04-15 Northwestern University Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
DK2723379T3 (en) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
JP2013059866A (ja) 2011-09-12 2013-04-04 Seiko Epson Corp 液体噴射装置、液体噴射装置の制御方法および液体噴射装置の制御プログラム
PT2771031T (pt) 2011-10-28 2018-05-24 Prothena Biosciences Ltd Anticorpos humanizados que reconhecem a alfa-sinucleína
SG11201408626YA (en) 2012-07-03 2015-03-30 Univ Washington Antibodies to tau
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
PL3071597T3 (pl) 2013-11-21 2020-11-30 F.Hoffmann-La Roche Ag Przeciwciała przeciwko alfa-synukleinie i sposoby stosowania
BR112016030183A2 (pt) * 2014-06-26 2017-11-14 Janssen Vaccines & Prevention Bv anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
CN107073297B (zh) * 2014-07-08 2021-09-14 纽约大学 Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
EA038358B1 (ru) 2016-06-02 2021-08-13 Медиммун Лимитед Антитела к альфа-синуклеину и их применение
MX2019005594A (es) 2016-11-15 2019-07-04 H Lundbeck As Agentes, usos y metodos para el tratamiento de la sinucleinopatia.
EP3661961A4 (en) * 2017-08-02 2021-04-14 Stressmarq Biosciences Inc. ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN

Also Published As

Publication number Publication date
CL2019001735A1 (es) 2019-10-04
US10364286B2 (en) 2019-07-30
EP3558364A1 (en) 2019-10-30
CA3046857A1 (en) 2018-06-28
CN110114088B (zh) 2023-08-15
CN110114088A (zh) 2019-08-09
MX2019007480A (es) 2019-08-29
KR20190098976A (ko) 2019-08-23
IL267559A (en) 2019-08-29
RU2019118922A (ru) 2021-01-22
WO2018115225A1 (en) 2018-06-28
RU2760334C2 (ru) 2021-11-24
US20180179273A1 (en) 2018-06-28
JP7300990B2 (ja) 2023-06-30
BR112018017172A2 (pt) 2019-01-02
JP2020504729A (ja) 2020-02-13
KR102584663B1 (ko) 2023-10-04
AU2017384681A1 (en) 2019-07-04
RU2019118922A3 (es) 2021-04-22

Similar Documents

Publication Publication Date Title
CO2019006059A2 (es) Anticuerpos monoclonales anti-alfa-sinucleína para prevenir la agregación de tau
CO2017012974A2 (es) Anticuerpos de unión a tau
EA202092435A2 (ru) Моноклональные антитела против bcma
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
SV2018005710A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
CO2017012971A2 (es) Anticuerpos de unión a tau
UY37381A (es) Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
BR112019012342A2 (pt) anticorpos il-11
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
EA201691991A1 (ru) Мультиспецифические антитела
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
GEP20217252B (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
BR112017007414A2 (pt) combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla